FDA Greenlights Gene Therapy, Because Patience Isn’t a Drug
In a plot twist worthy of a soap opera, the FDA announced it’s 'clearing the way' for Sarepta Therapeutics to resume shipments of their gene therapy for Duchenne muscular dystrophy to some patients. Yes, just some, because apparently miracles come with fine print. The FDA’s official line? They’re 'clearing the way,' which sounds a bit like popping open a space in traffic, except this lane could save lives. Gene therapy shipments resumed, but if you were hoping for a full-on party, well, it’s more of a dignified nod: progress served with a side of bureaucratic seasoning.
Share the Story
(1 of 3)FDA finally said 'go' for gene therapy shipments, or as they put it, 'clearing the way.' Someone tell my delivery app to work on that kind of speed. #MiracleMiles
Oh look, FDA is 'clearing the way' for some shipments like it's GPS rerouting around traffic jams. Your gene therapy might arrive sometime between now and the heat death of the universe.
Resuming gene therapy shipments to some patients is like giving only half your friends passes to the Electric Daisy Carnival—exclusive, selective, and sure to cause FOMO.
Source: Statnews | Published: 7/28/2025 | Author: Adam Feuerstein
More Articles in Health
OpenAI CEO’s $27M Mansion Molotoved Amid AI Lab Soap Opera
Sydney Sweeney's $1M Flop, Trump-Approved Jeans & Bathwater Soap Fiasco
Digital Nomad Trapped in Lisbon FOMO, Ends Up BFF Ghosted
Couple Rejects Costco Bulk, Returns to European Grocery Steps and Sanity
Woman Befriends Octogenarian, Learns Aging Is Just 'Old Lady' Bluntness
Woman’s Routine Eye Surgery Turns Into Unplanned MRI Brain Tumor Scare Roadshow
Health Secretary Trades Vaccines for Vegetable Advocacy and Congressional Grousing
Doctors Prescribe Fishing Rods—Because Pills Can’t Cast a Line
